Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
/in Dendritic Cells, International Publications, Malignant MelanomaMaking a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsAutologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro
/in Cervical Cancer, Dendritic Cells, International PublicationsMoving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
/in Dendritic Cells, International Publications, Prostate CancerCell Therapies in Bladder Cancer Management
/in Dendritic Cells, International Publications, Urothelial CarcinomaA Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
/in Dendritic Cells, International Publications, Malignant MelanomaASO Author Reflections: The Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine for Advanced-Stage Melanoma: Reflection on Personalized Cancer Vaccination
/in Dendritic Cells, International Publications, Malignant MelanomaTherapeutic efficacy of dendritic cell vaccine combined with programmed death 1 inhibitor for hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsDendritic cell vaccine therapy for colorectal cancer
/in Colorectal Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer